Prevalence of Extended Spectrum β-Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas from Patients of Khyber Pakhtunkhwa, Pakistan

Table 3

Yearwise susceptibility pattern (sensitivity) of Pseudomonas spp. to different antibiotics.

Agents	2010; (%)	2011; (%)	2012; (%)	2013; (%)	2014; (%)	Total; (%)
AML	10 (18.5)	14 (17.9)	13 (13.8)	8 (12.1)	5 (11.9)	50 (15.0)
AMC	17 (31.5)	22 (28.2)	18 (19.1)	17 (25.8)	8 (19.0)	82 (24.6)
TZP	35 (64.8)	47 (60.3)	57 (60.6)	40 (60.6)	24 (57.1)	203 (60.8)
SCF	42 (77.8)	55 (70.5)	63 (67.0)	45 (68.2)	26 (61.9)	231 (69.2)
CEC	13 (24.1)	17 (21.8)	19 (20.2)	14 (21.2)	8 (19.0)	71 (21.3)
CAZ	22 (40.7)	27 (34.6)	29 (30.9)	23 (34.8)	10 (23.8)	111 (33.2)
CRO	21 (38.9)	30 (38.5)	33 (35.1)	20 (30.3)	17 (40.5)	121 (36.2)
FEP	29 (53.7)	44 (56.4)	41 (43.6)	29 (43.9)	19 (45.2)	162 (48.5)
SPX	34 (63.0)	44 (56.4)	51 (54.3)	35 (53.0)	22 (52.4)	186 (55.7)
CIP	31 (57.4)	37 (47.4)	47 (50.0)	34 (51.5)	19 (45.2)	168 (50.3)
ENX	21 (38.9)	25 (32.1)	34 (36.2)	24 (36.4)	13 (31.0)	117 (35.0)
GTX	28 (51.9)	39 (50.0)	40 (42.6)	27 (40.9)	15 (35.7)	149 (44.6)
MXF	37 (68.5)	52 (66.7)	55 (58.5)	38 (57.6)	24 (57.1)	206 (61.7)
E	11 (20.4)	14 (17.9)	18 (19.1)	13 (19.7)	8 (19.0)	64 (19.2)
CLR	27 (50.0)	37 (47.4)	38 (40.4)	24 (36.4)	16 (38.1)	142 (42.5)
MEM	49 (90.7)	72 (92.3)	85 (90.4)	60 (90.9)	38 (90.5)	304 (91.0)
IPM	46 (85.2)	67 (85.9)	79 (84.0)	54 (81.8)	36 (85.7)	282 (84.4)
CN	11 (20.4)	15 (19.2)	18 (19.1)	11 (16.7)	7 (16.7)	62 (18.6)
AK	36 (66.7)	49 (62.8)	63 (67.0)	42 (63.6)	26 (61.9)	216 (64.7)
DO	7 (13.0)	9 (11.5)	9 (9.6)	6 (9.1)	3 (7.1)	34 (10.2)